What changed in this filing

/stocks — the workspaceLOADING

Item 5. Market for Registrant’s Common Equity

2023-03-30 compared with 2022-03-31 · 105 added, 18 removed, 17 unchanged (88% of the section changed)

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

common stock began trading on Nasdaq under the symbol “VVOS” on December 11, 2020.

Prior to that date, there was no established

public trading market for our common stock.

of March 23, 2022, there were approximately 5,400 holders of record of our common stock.

This number does not include stockholders who

are beneficial owners, but whose shares are held in street name by brokers and other nominees.

This number of holders of record also

does not include stockholders whose shares may be held in trust by other entities.

common stock is currently listed on the Nasdaq Capital Market under the symbol “VVOS”.

On March 28, 2023, the last

reported sale price of the shares of our common stock as reported on NASDAQ was $0.32 per share.

March 28, 2023, we had approximately 560 stockholders of record.

On March 28, 2023, there were 29,678,786 shares of our

common stock issued and outstanding.

In addition, we believe that a significant number of beneficial owners of our common stock hold

their shares in street name.

Sales of Unregistered Securities

following is a summary of transactions by us within the past three years involving sales or our securities that were not registered under

the Securities Act.

All of the sales listed below were made pursuant to an exemption from registration afforded by Section 4(a)(2) of

the Securities Act and/or Regulation D thereunder in that (i) none of the offers and sales constituted a public offering of securities

and/or (ii) the securities were only offered and sold to accredited investors.

November 2020, Vivos Therapeutics issued warrants to certain shareholders to purchase an aggregate of 325,000 shares of common stock.

Such warrants are substantially similar to the Series B Warrants except such warrants will be exercisable for a period of 36 months,

beginning six months after the consummation of the initial public offering and ending on the forty-second month anniversary of the consummation

of our initial public offering.

See “Management—October 2020 Derivative Demand and Settlement” in our Annual Report

on Form 10-K for the fiscal year ended December 31, 2020, filed with the SEC on March 25, 2021 for further information on the issuance

of these warrants.

March 12, 2021, Vivos Therapeutics granted options to purchase up to 145,000 shares of common stock at an exercise price of $7.50 share

in the following amounts to employees and consultants, 120,000 to two employees (100,000 and 20,000 respectively) with standard vesting

on each of the following dates:

(i) 20% as of the date of grant and (ii) 20% at the end of each year following the date of grant, and

25,000 to a consultant with standard vesting on each of the following dates:

(i) 20% as of the date of grant and (ii) 20% at the end

of each year following the date of grant.

March 29, 2021 and as part of the acquisition of certain assets from, and the entry into related agreements with, MyoCorrect, LLC and

its affiliates, Vivos Therapeutics issued three-year warrants to purchase 200,000 shares of our common stock with an exercise price of

$7.50 per share.

25,000 of these warrants vested initially upon issuance, but the remainder only vest and become exercisable upon the

achievement of pre-determined performance metrics related to the utilization of MyoCorrect.

These warrants may be exercised only for

cash, and the exercise price is subject to customary, stock-based anti-dilution protection.

April 14, 2021 and as part of the acquisition of certain assets from, and the entry into related agreements with, Lyon Management &

Consulting, LLC and its affiliates, we issued three year warrants to purchase 25,000 shares of our common stock with an exercise price

of $8.90 per share.

5,000 of these warrants vested initially upon issuance, but the remainder only vest and become exercisable at the

end of each anniversary year following the issuance date.

These warrants may be exercised only for cash, and the exercise price is subject

to customary, stock-based anti-dilution protection.

the period from March 12, 2021 through March 30, 2021, Vivos Therapeutics issued warrants to purchase an aggregate of 95,000 shares of

common stock to contractors and consultants in exchange for services.

These warrants have an exercise price of $7.50 per share.

of these warrants vested initially upon issuance, but the remainder only vest and become exercisable at the end of each anniversary year

following the issuance date.

These warrants may be exercised only for cash, and the exercise price is subject to customary, stock-based

anti-dilution protection.

February 25, 2022 the Company issued 290,000 stock options to certain employees and officers with an exercise price of $3.27 per share,

one-fifth vested on the date of grant, and one-fifth vests annually through February 25, 2026.

Additionally, the Company issued warrants

to purchase 80,000 shares of the Company’s common stock to certain consultants for sales consulting services with an exercise price

of $3.27 per share, vesting monthly over one year term of the agreement.

These warrants may be exercised only for cash, and the exercise

price is subject to customary, stock-based anti-dilution protection.

May 12, 2022, the Company issued 265,000 stock options to certain employees and officers with an exercise price of $1.29 per share, one-fifth

vested on the date of grant, and one-fifth vests annually through May 12, 2027.

Additionally, the Company issued warrants to purchase

130,000 shares of the Company’s common stock to certain consultants for sales consulting services with an exercise price of $1.29

40,000 of these warrants vested immediately upon issuance, 60,000 of these warrants vest monthly over a six month term and

30,000 of these warrants vest monthly over one year term of the agreement.

These warrants may be exercised only for cash, and the exercise

price is subject to customary, stock-based anti-dilution protection.

July 8, 2022, the Company issued 15,000 stock options to a certain employee with an exercise price of $1.45 per share, one-fifth vested

on the date of grant, and one-fifth vests annually through July 8, 2027.

December 23, 2022, the Company issued 1,404,168 stock options to certain employees and officers with an exercise price of $0.48 per share,

787,500 of these options vested one-fifth on the date of grant, and one-fifth vests annually through December 23, 2026, 160,000 of these

options vested 50% on the date of grant, and 25% vest on March 23, 2023, and the remaining 25% vest on June 23, 2023, and 456,668 of

these options vested immediately upon issuance.

Additionally, the Company issued warrants to purchase 850,000 shares of the Company’s

common stock to certain consultants for sales consulting services with an exercise price of $0.48 per share.

557,500 of these warrants

vested immediately upon issuance, 27,500 of these warrants vest quarterly over one year term, 115,000 of these warrants vest quarterly

over two year term of the agreement, 50,000 of these warrants vest annually over two year term, and 100,000 of these warrants exercisable

upon the achievement of pre-determined performance metrics.

These warrants may be exercised only for cash, and the exercise price is

subject to customary, stock-based anti-dilution protection.

January 5, 2023, the Company, closed a private placement (the “Private Placement”) pursuant to which the Company agreed sell

up to an aggregate of $8,000,000 of securities of the Company of units.

Each unit consists of one share of the Company’s common

stock, $0.0001 par value (or a pre-funded warrant to purchase one share of Common Stock) (the “Pre-Funded Warrants”) and

one warrant exercisable for one share Common Stock (the “Common Stock Purchase Warrants” and together with the Pre-Funded

Warrants, the “Warrants”).

No actual units will be issued in the Private Placement.

to the Purchase Agreement, the Company agreed to issue and sell in the Private Placement 2,000,000 Shares, Pre-Funded Warrants to purchase

up to an aggregate of 4,666,667 shares of Common Stock and Common Stock Purchase Warrants to purchase up to an aggregate of 6,666,667

shares of Common Stock (collectively with the shares of Common Stock underlying the Pre-Funded Warrants and the Warrants, the “Warrant

The purchase price per Share and associated Common Stock Purchase Warrant was $1.20, and the purchase price per Pre-Funded

Warrant and associated Common Stock Purchase Warrant was $1.1999.

Common Stock Purchase Warrant entitles the holder, for a period of five years and 6 months, to purchase one share of Common Stock at

an exercise price of $1.20 per share.

Each Pre-Funded Warrant entitles the holder, for a period until all Pre-Funded Warrants are exercised,

to purchase one share of Common Stock at an exercise price of $0.0001 per share.

The Warrants also contain customary beneficial ownership

limitations that may be waived at the option of each holder upon 61 days’ notice to the Company.

Authorized for Issuance under Equity Compensation Plans

following table provides information as of December 31, 2021, regarding our common stock that may be issued under our 2017 stock

and option award plan (the “2017 Plan”), and our 2019 stock and option award plan (the “2019 Plan”).

be Issued Upon

Weighted Average

following information is provided as of December 31, 2022, regarding our common stock that may be issued under our 2017 stock and option

award plan (the “2017 Plan”), and our 2019 stock and option award plan (the “2019 Plan”).

Shares to be Issued Upon

Exercise of Outstanding

Options, and Rights

Plan Category:

Equity compensation plans approved by security

Exercise Price

Equity compensation plans approved by security holders:

1,333,333 (1)

2,366,667 (2)

Equity compensation

plans not approved by stockholders:

2017 Plan permits grants of equity awards to employees, directors, consultants and other independent contractors.

Our Board of Directors

and shareholders have approved a total reserve of 1,333,333 shares for issuance under the 2017 Plan.

and stockholders have approved a total reserve of 1,333,333 shares for issuance under the 2017 Plan.

2019 Plan permits grants of equity awards to employees, directors, consultants and other independent contractors.

Our Board of Directors

and shareholders have approved a total reserve of 2,366,667 shares for issuance out of which 250,000 shares have been exercised under

and stockholders have approved a total reserve of 2,366,667 shares for issuance out of which 250,000 shares have been exercised under

the 2019 Plan.

options granted to officers and employees prior to the approval by our stockholders of the 2017 Plan.

of the date of this Annual Report on Form 10-K, we have not paid any cash dividends to stockholders.

4 unchanged sentences

dividends in the foreseeable future, but rather to reinvest earnings, if any, in our business operations.

of Equity Securities by the Issuer and Affiliated Purchasers.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 5. Market for Registrant’s Common Equity